LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

20.63 7.67

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.16

Massimo

20.65

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+101.4% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-84M 1.8B
Apertura precedente	12.96
Chiusura precedente	20.63

Notizie sul Sentiment di mercato

By Acuity

67%

33%

309 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

9.91 / 14.15 Supporto e resistenza

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mag 2026, 23:41 UTC

Utili

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mag 2026, 21:40 UTC

Utili

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mag 2026, 23:13 UTC

Utili

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mag 2026, 23:12 UTC

Utili

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mag 2026, 23:11 UTC

Utili

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mag 2026, 23:11 UTC

Utili

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mag 2026, 23:07 UTC

Utili

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mag 2026, 23:06 UTC

Utili

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mag 2026, 23:05 UTC

Utili

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mag 2026, 23:04 UTC

Utili

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mag 2026, 22:50 UTC

Utili

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mag 2026, 22:25 UTC

Discorsi di Mercato

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mag 2026, 22:11 UTC

Utili

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mag 2026, 22:05 UTC

Discorsi di Mercato

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mag 2026, 21:58 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:47 UTC

Discorsi di Mercato

Utili

Costco Posts 13% Sales Growth in April -- Market Talk

6 mag 2026, 21:46 UTC

Utili

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mag 2026, 21:40 UTC

Utili

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mag 2026, 21:35 UTC

Discorsi di Mercato

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mag 2026, 21:32 UTC

Azioni calde

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mag 2026, 21:29 UTC

Utili

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

101.4% in crescita

Previsioni per 12 mesi

Media 40.2 USD 101.4%

Alto 57 USD

Basso 29 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

9.91 / 14.15Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

309 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.